news
COVID-19 vaccines will require outsourced manufacturing, says report
The pharma industry will need to outsource manufacturing for COVID-19 vaccine doses for booster doses and children, reports GlobalData.
List view / Grid view
GlobalData
news
Increase in virtual trials improves patient accrual rates, finds report
The increased use of virtual components in clinical trials has led to fewer trial delays or terminations due to low participant numbers.
news
Gene therapies set to revolutionise cardiovascular treatments
Gene therapies could revolutionise management of cardiovascular diseases such as heart failure, according to a GlobalData report.
news
Parkinson’s disease market sales to reach $11.5 billion in 2029
The Parkinson’s disease market is set to triple in sales by 2029 driven by novel biologics and delivery systems, reports GlobalData.
news
LBPs may offer hope to IBS patients in the near future, says report
Live biotherapeutic products (LBPs) are expected to help patients with IBS who currently have no US- or EMA-approved treatments.
news
2021 a pivotal year for personalised neoantigens, says GlobalData
With multiple catalysts coming up in late 2021, GlobalData reports a boom in the field of personalised neoantigen immuno-oncology therapeutics.
news
AI and big data will continue to disrupt pharma sector, says survey
A GlobalData report has revealed the extent to which companies will be using AI and big data in drug discovery and development processes.
news
Chinese patent reforms to bolster pharma innovation
Market research suggests the new drug patent reforms in China, in addition to other regulatory changes, will incentivise innovative pharma research.
news
Alzheimer’s drug Aduhelm™ authorised in US under accelerated approval
Aduhelm™ (aducanumab-avwa) is the first new treatment approved for Alzheimer’s since 2003 and the first therapy to target the fundamental pathophysiology of the disease – amyloid plaques.
news
Competition and Markets Authority investigating AstraZeneca’s Alexion acquisition
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
news
Industry hustling to ensure supply of recombinant vector COVID-19 vaccines
A new report suggests pharma is working hard to combat worldwide viral vectors shortage that could threaten the COVID-19 vaccine rollout.
news
CMOs should invest in biologic API manufacturing capabilities, says GlobalData
Research shows the complexity and number of biologics is increasing, as is the frequency at which their active pharmaceutical ingredient (API) production is outsourced.
news
COVID-19 manufacturing requirements are lucrative for CMOs, says GlobalData
A new report shows half the drugs and all the vaccines approved for emergency use in 2020 had an associated contract manufacturing agreement.
news
Could viral vector shortages disrupt the COVID-19 vaccine roll-out?
According to GlobalData, AstraZeneca’s and Janssen’s COVID-19 vaccines could be impacted by global viral vector shortages.
news
CRISPR therapies could be one of the most transformative in human history, says GlobalData
Adam Pearson, Senior Oncology Analyst at GlobalData, comments on the development of CRISPR-based therapies and outlines potential opportunities and challenges in the space.